Cellectar Biosciences (CLRB) EPS (Basic) Growth (3y) (2013 - 2026)
Cellectar Biosciences (CLRB) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | -38.31% |
| 10 | Cellectar Biosciences | 6.72 Mn | 6.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.25% |
| Dec 31, 2025 | 81.28% |
| Sep 30, 2025 | 65.76% |
| Jun 30, 2025 | 51.69% |
| Mar 31, 2025 | 47.88% |
| Dec 31, 2024 | -43.60% |
| Sep 30, 2024 | 29.89% |
| Jun 30, 2024 | 30.89% |
| Mar 31, 2024 | 31.38% |
| Dec 31, 2023 | 15.32% |
| Sep 30, 2023 | 17.92% |
| Jun 30, 2023 | 34.76% |
| Mar 31, 2023 | 43.61% |
| Dec 31, 2022 | -37.26% |
| Sep 30, 2022 | 31.89% |
| Jun 30, 2022 | 39.97% |
| Mar 31, 2022 | 52.27% |
| Dec 31, 2021 | 55.90% |
| Sep 30, 2021 | 60.28% |
| Jun 30, 2021 | 61.60% |